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Summary
Background Pelvic organ prolapse is common and is strongly associated with childbirth and increasing age. Women 
with prolapse are often advised to do pelvic fl oor muscle exercises, but evidence supporting the benefi ts of such 
exercises is scarce. We aimed to establish the eff ectiveness of one-to-one individualised pelvic fl oor muscle training 
for reducing prolapse symptoms.
Methods We did a parallel-group, multicentre, randomised controlled trial at 23 centres in the UK, one in New 
Zealand, and one in Australia, between June 22, 2007, and April 9, 2010. Female outpatients with newly-diagnosed, 
symptomatic stage I, II, or III prolapse were randomly assigned (1:1), by remote computer allocation with minimsation, 
to receive an individualised programme of pelvic fl oor muscle training or a prolapse lifestyle advice leafl et and no 
muscle training (control group). Outcome assessors, and investigators who were gynaecologists at trial sites, were 
masked to group allocation; the statistician was masked until after data analysis. Our primary endpoint was 
participants’ self-report of prolapse symptoms at 12 months. Analysis was by intention-to-treat analysis. This trial is 
registered, number ISRCTN35911035.
Findings 447 eligible patients were randomised to the intervention group (n=225) or the control group (n=222). 
377 (84%) participants completed follow-up for questionnaires at 6 months and 295 (66%) for questionnaires at 
12 months. Women in the intervention group reported fewer prolapse symptoms (ie, a signifi cantly greater reduction 
in the pelvic organ prolapse symptom score [POP-SS]) at 12 months than those in the control group (mean reduction 
in POP-SS from baseline 3·77 [SD 5·62] vs 2·09 [5·39]; adjusted diff erence 1·52, 95% CI 0·46–2·59; p=0·0053). 
Findings were robust to missing data. Eight adverse events (six vaginal symptoms, one case of back pain, and one 
case of abdominal pain) and one unexpected serious adverse event, all in women from the intervention group, were 
regarded as unrelated to the intervention or to participation in the study.
Interpretation One-to-one pelvic fl oor muscle training for prolapse is eff ective for improvement of prolapse symptoms. 
Long-term benefi ts should be investigated, as should the eff ects in specifi c subgroups.
Funding Chief Scientist Offi  ce of the Scottish Government Health and Social Care Directorates, New Zealand Lottery 
Board, and National Health and Medical Research Council (Australia).
Copyright © Hagen et al. Open Access article distributed under the terms of CC BY.
Introduction
Pelvic organ prolapse is a common disorder in 
women—40% of women older than 50 years have some 
degree of prolapse on examination.1 About 11% of women 
undergo surgery for urinary incontinence or prolapse in 
their lifetime, and 7% for prolapse alone.2 In England, 
about 29 000 prolapse repairs were done between 2010 and 
2011,3 at a cost of around £60 million, and numbers of 
women undergoing surgery are likely to increase 
substantially as the population ages.4 Increasing age and 
parity, and a family history of prolapse, are the main risk 
factors for prolapse, although factors such as obesity, heavy 
lifting, and constipation can also have a role.5 One study 
reported a total population-attributable risk for prolapse of 
46%, which was associated with women having prolapse 
symptoms during pregnancy, a mother with prolapse, and 
undertaking heavy physical work.6 Prolapse is characterised 
by symptomatic descent of the vaginal walls, apex, or vault 
from the normal anatomical position.7 Women with 
prolapse might present with vaginal, bladder, bowel, back, 
abdominal, and sexual symptoms. The disorder can aff ect 
daily activity and quality of life. Treatment options include 
surgery and conservative management, of which the latter 
is used commonly if the prolapse is low in severity or the 
woman is not a candidate for surgery. Conservative 
interventions include physical interventions to improve 
the function and support of the pelvic fl oor muscles via 
pelvic fl oor muscle training; mechanical interventions (eg, 
use of vaginal pessaries) to support the prolapse; and 
lifestyle interventions (eg, weight loss and avoiding of 
heavy lifting) to avoid exacerbation of the prolapse by 
decreasing intra-abdominal pressure.
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See Online for appendixMany physiotherapists who specialise in women’s health 
off er women with prolapse individualised pelvic fl oor 
muscle training.8 The aim of muscle training is to improve 
the function of the pelvic fl oor muscles—ie, strength, 
endurance, and coordination—and to ultimately increase 
the structural support for the pelvic organs. A Cochrane 
review9 showed that training of the pelvic fl oor muscles 
was eff ective for treatment of urinary incontinence. 
Evidence for the management of prolapse is less clear. A 
separate Cochrane review10 identifi ed four trials (including 
two pilot trials) comparing individuals undergoing pelvic 
fl oor muscle training with control groups; two of which 
were at signifi cant risk of bias. Symptoms, although 
measured diff erently in diff erent studies, were improved 
in the short term in three trials, and pooled data for severity 
from two trials showed an improvement in prolapse after 
treatment due to muscle training. The review concluded 
that reliable evidence is needed about the medium-term 
and long-term eff ectiveness and cost-eff ectiveness of pelvic 
fl oor muscle training.
We did the Pelvic Organ Prolapse PhysiotherapY 
(POPPY) trial to assess whether one-to-one pelvic fl oor 
muscle training would reduce the symptoms of prolapse 
and the need for further prolapse treatment in women 
with stage I–III prolapse, and whether it would be a cost-
eff ective option, compared with a prolapse lifestyle advice 
leafl et.
Methods
Study design and participants
We did this parallel-group, multicentre, randomised trial 
between June 22, 2007, and April 9, 2010, in new attendees 
at outpatient gynaecology clinics who presented with 
symptomatic prolapse at 25 centres (23 in the UK; one in 
Dunedin, New Zealand; and one in Sydney, Australia). 
Centres were a mixture of university teaching hospitals 
and district general hospitals, and all off ered similar 
specialist pelvic fl oor physiotherapy services. Eligible 
women of any age had stage I–III prolapse of any type 
(anterior, posterior, apical, or a combination) as confi rmed 
by their gynaecologist on vaginal examination with the 
pelvic organ prolapse quantifi cation (POP-Q) system,11 
and had prolapse as their main presenting complaint. We 
excluded women who had received previous treatment for 
prolapse, including surgery; who were pregnant or less 
than 6 months postnatal; or who were unable to comply 
with the intervention (ie, if they were not able to attend the 
clinic for appointments with the physiotherapist). Women 
who needed treatment for vaginal atrophy were eligible 
after completing a course of local oestrogens.
We based the trial methods on fi ndings from our pilot 
trial.12 Women provided signed informed consent. We did 
the trial in accordance with the Declaration of Helsinki. 
Approval was obtained from the Scotland A Research 
Ethics Committee, the Lower South Regional Ethics 
Committee, the Human Research Ethics Committees of 
The University of Melbourne, and from St George 
Hospital (Kogarah, NSW, Australia). An independent 
Trial Steering Committee and a separate independent 
Data Monitoring Committee oversaw the trial. Full details 
of the study protocol are available online.
Randomisation and masking
Patients were randomly assigned (1:1), with the remote-
computer-determined randomisation application at the 
Centre for Healthcare Randomised Trials (University of 
Aberdeen, UK), to receive an individualised programme 
of pelvic fl oor muscle training or a prolapse lifestyle 
advice leafl et and no muscle training (control group). 
Randomisation used a minimisation approach to balance 
group sizes for key prognostic factors at baseline. Factors 
were centre, stage of prolapse (I, II, or III), and the 
motivation for prolapse surgery (ie, women not 
considering surgery versus those considering surgery). 
Motivation for surgery is a potentially important factor 
aff ecting how adherent women will be to pelvic fl oor 
muscle training. The university-based trial coordinator 
accessed the web-based application and then informed 
the woman, and the physiotherapist as necessary, of the 
allocated group. The intervention could not be masked 
from women or treating physiotherapists. The 
researchers who coordinated data entry and management 
(SD, JL, GMcP) were remote from the clinical sites and 
therefore did not have contact with patients. Outcome 
assessment was by participant-completed questionnaires, 
thus avoiding assessor bias; data-entry staff  were masked 
to group allocation. The gynaecologists undertaking the 
POP-Q assessment at 6 months, including those who 
were investigators (CG, KHM, and DW), were masked to 
group allocation until after the examination. The 
statistical analyst (SB) was independent of the research 
team and was masked to group allocation until after the 
main analysis had been undertaken.
Procedures
Women allocated to the intervention were invited to 
attend fi ve one-to-one appointments for pelvic fl oor 
muscle training over 16 weeks (at weeks 0, 2, 6, 11, and 16) 
with a women’s health physiotherapist. The duration of 
16 weeks was chosen on the basis of muscle physiology 
(15 weeks of specifi c muscle training is needed to gain 
muscle hypertrophy13) and UK clinical guidelines for the 
management of urinary incontinence, which recommend 
muscle training for “at least 3 months”.14 Appointment 
frequency was based on present practice within the UK 
National Health Service (NHS)—ie, fi rst appointments 
close together to allow reinforcement of correct exercise 
technique and understanding of all advice given, later 
appointments becoming further apart to encourage 
independent home exercise.
At the fi rst appointment an explanation of types of 
prolapse, anatomy and function of pelvic fl oor muscles 
was given with use of diagrams and a model pelvis. 
Internal assessment of the pelvic fl oor muscles was done 
For the study protocol see 
https://w3.abdn.ac.uk/hsru/
poppy/Public/DownloadPage.
aspx
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to correct exercise technique and assess muscles (using 
the PERFECT Scheme).15 An individualised home 
exercise programme was prescribed on the basis of 
examination fi ndings. Women were encouraged to 
progress exercises, with an aim of ten times 10 s 
maximum holds and up to 50 fast contractions three 
times per day, and to record all exercises in a diary. 
Furthermore, women were taught how to precontract the 
pelvic fl oor muscles against increases in intra-abdominal 
pressure (so-called the Knack exercise) and were 
encouraged to use this technique daily. The home 
exercise programme was modifi ed at each appointment 
on the basis of examination fi ndings and diary 
recordings. Use of electromyography biofeedback, 
pressure biofeedback, and electrical stimulation were not 
permitted. Trial physiotherapists attended training 
before their involvement in intervention delivery within 
the trial. No additional training was given to 
physiotherapists during intervention delivery.
Participants received a prolapse lifestyle advice leafl et 
that gave advice about weight loss, constipation, avoidance 
of heavy lifting, coughing, and high-impact exercise; 
women in the control group received this leafl et by post, 
whereas women in the intervention group received it at 
their fi rst appointment. The leafl et contained no 
information about pelvic fl oor muscle exercises or 
techniques. Women attended a review appointment with 
their gynaecologist 6 months after trial entry, at which 
time they could be referred for further treatment if 
desired.
We used postal questionnaires to collect data at baseline, 
and 6 months and 12 months after trial entry. Our primary 
endpoint was prolapse symptoms at 12 months as 
measured by the pelvic organ prolapse symptom score 
(POP-SS),16 a validated, patient-completed method with 
seven items relating to frequency of prolapse symptoms 
in the previous 4 weeks; each item is scored from 0 
(never) to 4 (all of the time), with a possible total score 
ranging from 0 to 28. Secondary outcomes were women’s 
perceived change in prolapse since the start of the study 
(same, better, or worse); quality of life, measured as 
interference of prolapse symptoms with everyday life 
(scored 0 [not at all] to 10 [a great deal]); number of days 
with prolapse symptoms in the previous 4 weeks; uptake 
of further prolapse treatment (surgery, pessary, referral to 
physiotherapy, referral to dietitian, oestrogen cream or 
tablets, or hormone replacement therapy); severity of 
incontinence (International Consultation on Incontinence 
Questionnaire—Urinary Incontinence Short Form, 
scored from 0 to 21, with higher values showing greater 
severity);17 bowel symptoms (early short form version of 
International Consultation on Incontinence 
Questionnaire—bowels module, as provided by the 
developers); sexual symptoms (Pelvic Organ Prolapse/
Urinary Incontinence Sexual Questionnaire);18 general 
health (12-Item Short Form Health Survey);19 use of health 
services in primary and secondary care; and frequency of 
the practice of pelvic fl oor muscle exercises in the past 
4 weeks (a few times only, once a week, a few times a 
week, once a day, a few times a day; and contractions per 
day less than fi ve, fi ve to ten, 11–20, 21–30, 31–60, >60). 
Intervention adherence was measured in terms of 
attendance at appointments and the amount of exercise 
women recorded in their daily exercise diary. Additionally, 
at each appointment, the physiotherapists delivering the 
intervention collected data about women’s adherence to 
the prescribed exercise.
The clinics’ gynaecologists used the POP-Q system to 
assess prolapse type and stage in all women before group 
allocation and at the 6 month review appointment.11 
Formal POP-Q training was given at each trial centre 
initiation visit. This training included a verbal explanation 
of the POP-Q system; observation of the American 
Urogynecological Society POP-Q training DVD; 
information about standardisation of conditions for 
POP-Q examination (eg, examination position, bladder 
emptying, and equipment use); and use of the recording 
form and a question and answer session. Each centre 
was given a copy of the DVD and the publication 
describing the POP-Q.11 Centres were encouraged to 
undertake further in-house training, and additional 
centre visits were off ered if necessary.
Statistical analysis
We estimated a mean diff erence between groups in POP-
SS of 2·5 (SD 8) as our eff ect size, on the basis of fi ndings 
from our pilot trial.12 With 253 women per group, the trial 
had 80% power at a 5% signifi cance level to detect a 
diff erence of 2·5 points in the primary outcome measure, 
assuming a common SD of 8 points.20 This calculation 
allowed for a 10% overall loss to follow-up, and 15% of 
the control group receiving all the benefi t of muscle 
training by undertaking exercises with their own 
initiative.
We tabulated descriptive statistics, reporting baseline 
demographics and clinical characteristics with means 
and SDs, or medians and IQRs as appropriate. We used 
intention-to-treat analyses to compare the primary 
outcome at 12 months by fi tting a linear mixed-eff ects 
model to change from baseline in POP-SS at 6 months 
and 12 months, with a random intercept for patient 
within centre, and a random slope for time within 
patient, and adjusted for baseline POP-SS score and the 
minimisation variables. Such models implicitly adjust 
the model estimates when data are missing, with an 
assumption that data are missing at random, according 
to reported values.21 We included women who had 
observations at baseline and at least one follow-up 
timepoint in the model. We present the diff erence 
between the intervention and control groups in 
estimated mean change from baseline for 6 months and 
12 months with 95% CIs and p values. We also used 
multiple imputation to assess the assumption of data 
missing at random and the corresponding eff ect of 
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missing responses on the primary outcome.22 Model 
assumptions were checked with residual plots and were 
shown to hold.
We compared POP-Q stage between groups in an 
ordinal regression model with 6 month POP-Q stage as 
the dependent variable and baseline POP-Q stage and 
minimisation variables as covariates. The pooled odds 
ratio (OR) from the ordinal model was calculated with a 
95% CI and p value. Stage II prolapse was subdivided 
into two groups dependent on whether the prolapse was 
above the hymen or at the hymen or below. Change in 
POP-Q stage between baseline and 6 months was also 
presented. Other secondary outcomes were compared 
between groups with the Mann-Whitney U test for 
continuous and ordinal variables and the χ² or Fisher’s 
exact test for categorical variables.
With planned subgroup analyses we explored the eff ect 
of prolapse stage and type, age, and motivation for 
surgery on the primary outcome, with stricter levels of 
signifi cance (two-sided p<0·01) than those used for other 
analyses.
Analyses were done according to a pre-specifi ed 
statistical analysis plan using the R programming package 
(version 2.15.0)23 and the mi package in R (version 0.09-
17)24 for post-hoc multiple imputation analysis.
Our economic assessment was a within-trial analysis 
12 months after recruitment, with a cost perspective of 
the UK NHS. We used direct health-service costs to 
generate the total cost for each participant. On the basis 
of the number of physiotherapy appointments attended 
during the trial, we estimated the amount of 
physiotherapy time involved in the delivery of the 
intervention and the associated costs of clinic space. All 
women were asked in follow-up questionnaires about 
their use of health services (consultations with their 
family doctor or a practice nurse) and any further 
prolapse treatment they had received. Costs were 
attributed to these items with UK data from the Personal 
Social Services Research Unit, Unit Costs of Health and 
Social Care; Scottish Health Service Costs; British 
National Formulary; and C&G Medicare.25–28 The costs 
were balanced against changes in the primary clinical 
outcome. We assumed that diff erences between trial 
groups in rates of subsequent treatments, such as, 
surgery at the end of the trial follow-up period represented 
savings. We did sensitivity analyses to assess the possible 
eff ects of varying of the intervention eff ect size and the 
uptake of subsequent prolapse treatment.
This trial is registered, number ISRCTN35911035.
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. GM, JN, SB, AE, SH, and AW had 
access to all the data in the study and all authors had 
fi nal responsibility for the decision to submit for 
publication.
Results
The fi gure shows the trial profi le. 447 eligible patients were 
randomised to the intervention group (n=225) or the 
control group (n=222). 377 (84%) participants completed 
follow-up for questionnaires at 6 months and 295 (66%) 
for questionnaires at 12 months (fi gure); 365 (82%) women 
attended for 6 month review. Non-responders at 12 months 
were signifi cantly younger and had a higher body-mass 
index (BMI) than did responders (data not shown). We 
noted no evidence of diff erential dropout between the trial 
groups (fi gure). Table 1 shows baseline clinical and 
demographic characteristics. The mean age of participants 
was 56·8 years (SD 11·5); the median number of births per 
woman was two (range zero to seven); 412 (93%) of 
445 women had had at least one vaginal birth, 28 (6%) 
of 447 had had at least one caesarean section, 118 (26%) of 
445 had had at least one forceps delivery, and 9 (2%) of 
447 had had a vacuum extraction. Two (<1%) patients were 
missing the delivery type for a total of three births between 
them, explaining the denominator of 445 for these 
calculations. Women were on average overweight (mean 
BMI 27 [SD 5·1]). The most common presentation was 
combined anterior, posterior, and upper compartment 
For the R programming 
package see http://
www.R-project.org/
Figure: Trial profi le
POP-Q=pelvic organ prolapse quantifi cation. *Did not attend any appointments. †Withdrew from questionnaire 
follow-up.
2093 women assessed for eligibility
477 randomised
1646 excluded
 1490 did not meet inclusion criteria
 156 declined to participate
225 allocated to intervention group
 212 received allocated intervention
 10 did not receive allocated intervention*
 3 had missing data 
222 allocated to control group
14 lost to follow-up†
30 discontinued intervention
 7 did not have time to participate
 7 did not attend or rearrange appointments
 5 became ineligible after randomisation
 5 were referred for surgery
 3 had difficulties arranging travel to
  appointments
 2 thought muscle training worsened their
  symptoms
 1 declined to complete 12 month questionnaire
12 lost to follow-up†
Analysed
225 at baseline
189 at 6 month questionnaire
168  at 6 month POP-Q
150  at 12 month questionnaire
Analysed
222  at baseline
189 at 6 month questionnaire
171 at 6 month POP-Q
145 at 12 month questionnaire
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prolapse, followed by combined anterior and posterior 
(table 1). Stage II prolapse was the most common type and 
most women had stage II prolapse at or below the hymen 
(table 1). Median duration of prolapse symptoms was 
12 months (table 1). As expected for a trial of this size, the 
clinical and demographic factors at baseline were similar 
between groups (table 1).
178 (80%) of 222 women in the intervention group 
attended four or fi ve of the possible fi ve physiotherapy 
appointments during the 16 week intervention period 
(table 2). Mean interappointment adherence to the 
prescribed number of sets of exercise or greater was 72% 
(range 53–79). Women in the intervention group were 
more likely than those in the control group, although not 
signifi cantly so, to report undertaking of pelvic fl oor 
exercises in the last 4 weeks at 12-month follow-up 
(115 [78%] of 147 vs 95 [69%] of 138 women; risk diff erence 
9·4%, 95% CI –0·8 to 19·6, p=0·07; risk ratio 1·13, 
95% CI 0·96–1·34, p=0·15).
Eight adverse events (six vaginal symptoms, one case of 
back pain and one of abdominal pain) and one 
unexpected serious adverse event (a skiing injury), 
defi ned as aff ecting normal daily life, were reported; all 
reports were from women in the intervention group. No 
event was deemed to be related to the intervention or to 
trial participation.
Women in the intervention group reported greater 
improvement in prolapse symptoms (a signifi cantly 
greater reduction in POP-SS) than those in the control 
group at both 6 months and 12 months (table 3). When we 
combined the results from refi tting of the model to fi ve 
imputations of the missing POP-SS scores, estimates of 
the diff erences between the groups were very similar to 
those from the original model (6 months 2·79, 1·91–3·67; 
12 months 1·66, 0·74–2·58). The most commonly 
reported symptom at baseline was “a feeling of something 
coming down” (table 1); this fi nding persisted at 6 months 
and 12 months (table 3). All POP-SS symptoms were 
signifi cantly less common in the intervention group than 
the control group at 6 months (table 3); at 12 months 
“discomfort worse when standing” and “lower abdominal 
heaviness” were signifi cantly less common (table 3). 
Women in the intervention group were less likely than 
those in the control group to report prolapse symptoms in 
the last 4 weeks, both at 6 months and 12 months (table 3).
When asked “how do you feel your prolapse is now 
compared to the start of the study?”, women in the 
intervention group were signifi cantly more likely than 
those in the control group to report that their prolapse 
was “better”, both at 6 months and 12 months (table 3).
After adjustment for baseline POP-Q stage, centre, and 
whether the woman was motivated to have surgery, the 
odds of women having a low-severity of prolapse at 
6 months were greater in the intervention group than in 
the control group, although this diff erence was not 
signifi cant (OR 1·47, 95% CI 0·97–2·27; p=0·07). A 
greater proportion of women in the intervention group 
Intervention (N=225) Control (N=222)
Age (years) 56·20 (11·60) 57·50 (11·39)
BMI (kg/m2) 27·15 (4·99), n=214 27·42 (4·57), n=210
Parity 2 (2–3), n=223 2 (2–3), n=217
Stage of prolapse*
Stage I 23 (10%) 18 (8%)
Stage II (above the hymen) 48 (21%) 47 (21%)
Stage II (at or below the hymen) 116 (52%) 127 (57%)
Stage III 38 (17%) 29 (13%)
Stage IV 0 1 (<1%)
Type of prolapse
Anterior 23 (10%) 25/220 (11%)
Posterior 13 (6%) 11/220 (5%)
Anterior and posterior 54 (24%) 54/220 (24%)
Anterior and upper 27 (12%) 22/220 (10%)
Posterior and upper 6 (3%) 8/220 (4%)
Anterior and posterior and upper 102 (45%) 100/220 (46%)
Duration of prolapse symptoms in months 12 (6–24), n=196 12 (6–24), n=201
Baseline POP-SS† 10·04 (6·0), n=224 9·51 (5·64), n=222
Symptom reported in last 4 weeks
Something coming down 193/219 (88%) 195/219 (89%)
Discomfort worse when standing 140/221 (63%) 147/220 (67%)
Abdominal pain when standing 153/222 (69%) 145/217 (67%)
Lower-back heaviness 131/222 (59%) 125/216 (58%)
Strain to empty bladder 138/221 (62%) 109/218 (50%)
Feel bladder not empty 159/221 (72%) 152/218 (70%)
Feel bowel not empty 154/221 (70%) 140/222 (63%)
Faecal urgency‡ 138/223 (62%) 135/221 (61%)
Faecal incontinence‡ 60/223 (27%) 55/222 (25%)
Urinary incontinence 145/225 (64%) 156/221 (71%)
Urinary incontinence score (ICIQ-UI SF§) 4 (0–7), n=218 4 (0–7), n=216
Data are mean (SD), median (IQR), n (%), or n/N (%), unless otherwise indicated. BMI=body-mass index. 
POP-SS=pelvic organ prolapse symptom score. ICIQ-UI SF=International Consultation on Incontinence 
Questionnaire Urinary Incontinence Short Form. *Pelvic organ prolapse quantification (POP-Q) stage reported 
here was calculated at the analysis stage with a specially developed programme that used the nine individual 
POP-Q measurements recorded by the gynaecologist. On occasion this stage differed from that assigned by the 
gynaecologist that identified women’s trial eligibility. †POP-SS: 0=no symptoms, 28=all seven symptoms all the 
time. ‡We defined faecal urgency as a sudden, irresistible need to have a bowel movement; faecal incontinence 
was any involuntary loss of faecal material. §ICIQ-UI SF score: 0=no incontinence, no interference with everyday 
life; 21=maximum leakage and interference.
Table 1: Baseline characteristics
Number of women attending (N=222*)
0 10 (5%)
1 9 (4%)
2 10 (5%)
3 15 (7%)
4 22 (10%)
5 156 (70%)
Data are n (%), unless otherwise indicated. *Missing data for three women from 
the intervention group.
Table 2: Number of physiotherapy appointments attended by women in 
the intervention group
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than in the control group had an improvement in their 
prolapse stage by 6 months (table 4), but this diff erence 
was not signifi cant (risk diff erence 7·5%, 95% CI –1·4 to 
16·4, p=0·10; risk ratio 1·39, 95% CI 0·94–2·06, p=0·10). 
At 12 months, signifi cantly more women in the control 
group than the intervention group had received further 
treatment (table 4; risk diff erence 25·5%, 14·5–36·0, 
p<0·0001; risk ratio 2·1, 1·5–2·9, p<0·0001). We noted a 
similar uptake of surgery, pessary, and other non-trial 
treatments in the study groups at 12 months, but 
signifi cantly more women in the control group had had a 
physiotherapy referral for pelvic fl oor muscle training 
(table 4).
Women were asked to report to what extent prolapse 
interfered with dimensions of their quality of life and 
about other symptoms (table 5). At 6 months, scores in 
women in the intervention group were signifi cantly 
lower (ie, better) than those in women in the control 
group for all aspects of daily life, and sexual, bladder, 
and bowel function (except for faecal incontinence), but 
this fi nding was not evident at 12 months (table 5). The 
treatment eff ect at 12 months was consistent for all 
prespecifi ed subgroups. We recorded no signifi cant 
interactions between trial group and any of the subgroup 
terms in the model: prolapse stage I–III (p=0·38); 
prolapse type of most descended part anterior, posterior, 
or upper (p=0·61); age younger than 50 years or 50 years 
and older (p=0·29); and motivation for surgery as keen 
or wants to avoid (p=0·89).
The cost of the physiotherapy intervention was £170·24 
on the basis of an hourly cost of £30·67 for a band 6 
physiotherapist.25 Trial physiotherapists reported that 
initial appointments took 80 min (60 min face-to-face 
plus 20 min of administration); follow-up appointments 
(maximum of four) took 40 min. For overheads such as 
the cost of the examination room, a fi gure of £16 per 
appointment was used.26 On average women attended for 
4·2 sessions of the possible fi ve; therefore, we applied an 
84% uptake rate. On the basis of the questionnaire 
responses regarding further treatment received, and of 
published cost estimates of the various treatment courses 
(surgery £1044,26 pessary £229·45,27,28 referral for 
6 months 12 months
Intervention (n=225) Control
(n=222)
Adjusted diff erence 
in mean change from 
baseline,* or p value
Intervention (n=225) Control
(n=222)
Adjusted diff erence in 
mean change from 
baseline,* or p value
POP-SS† 6·56 (5·09), n=188 9·17 (5·81), n=189 .. 5·74 (4·89), n=145 7·04 (5·43), n=139 ..
Reduction in POP-SS from baseline 3·16 (4·78) 0·12 (3·86) 2·84 (2·05–3·63);
p<0·0001
3·77 (5·62) 2·09 (5·39) 1·52 (0·46–2·59); 
p=0·0053
Prolapse symptoms reported in last 4 weeks
Feeling of something coming down 136/185 (73%) 162/187 (87%) 0·0001 98/139 (70%) 102/138 (74%) 0·09
Discomfort worse when standing 81/184 (44%) 122/185 (66%) <0·0001 54/141 (38%) 78/137 (57%) 0·0016
Abdominal pain when standing 89/187 (48%) 114/184 (62%) 0·0001 56/143 (39%) 69/135 (51%) 0·0077
Lower-back heaviness 88/187 (47%) 108/182 (59%) 0·0036 63/143 (44%) 68/137 (50%) 0·10
Strain to empty bladder 87/185 (47%) 106/185 (57%) 0·0325 67/143 (47%) 64/136 (47%) 0·95
Feel bladder not empty 109/187 (58%) 129/184 (70%) 0·0009 80/144 (56%) 85/137 (62%) 0·56
Feel bowel not empty 111/187 (59%) 134/184 (73%) 0·0014 85/140 (61%) 91/137 (66%) 0·41
Days with prolapse symptoms in the last 
4 weeks‡
137/185 (74%) 162/186 (87%) 0·0001 95/143 (66%) 104/139 (75%) 0·0233
How prolapse is now compared with at the start of the study
Better 98/187 (52%) 32/189 (17%) <0·0001 83/145 (57%) 63/141 (45%) 0·0125
The same 77/187 (41%) 114/189 (60%) .. 49/145 (34%) 52/141 (37%) ..
Worse 12/187 (6%) 43/189 (23%) .. 13/145 (9%) 26/141 (18%) ..
Data are diff erence (95% CI) or n/N (%), unless otherwise indicated. POP-SS=pelvic organ prolapse symptom score. *Adjusted for baseline POP-SS, Pelvic organ prolapse quantifi cation (POP-Q) stage, centre, and 
whether or not the woman was motivated to have surgery. †POP-SS: 0=no symptoms, 28=all seven symptoms all the time. ‡The question about the number of days with symptoms had a seven-category 
response, from 0 (none of the time) to 6 (every day). We used the Mann-Whitney U test for the number of categories changed since baseline. 
Table 3: Self-reported prolapse symptoms at 6 months and 12 months 
Intervention (n=168) Control (n=171) p value
+2 stages 4/168 (2%) 9/171 (5%) ··
+1 stage 26/168 (16%) 29/171 (17%) ··
no change 93/168 (55%) 100/171 (58%) ··
−1 stage 34/168 (20%) 25/171 (15%) ··
−2 stages 11/168 (7%) 8/171 (5%) ··
Further treatment received by 12 months
Any further treatment received 35/145 (24%) 71/143 (50%) <0·0001
Surgery 16/145 (11%) 14/143 (10%) 0·84
Pessary 8/145 (5%) 16/143 (11%) 0·13
Physiotherapy referral 2/145 (1%) 38/143 (27%) <0·0001
Oestrogen, drugs, or other 14/145 (10%) 15/143 (11%) 0·85
Table 4: Change in prolapse (pelvic organ prolapse quantifi cation) stage at 6 months, and uptake of 
further prolapse treatment by 12 months
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physiotherapy £170·24, oestrogen or HRT £195·5127), the 
diff erence between the groups in mean cost of subsequent 
treatment was £38·63 (95% CI –41·95 to 126·41; p=0·34). 
The mean cost per woman in the control group was 
£306·86 (250·74–368·29) and per woman in the 
intervention group was £268·23 (210·35–333·59). 
Overall, the net cost of the intervention per woman was 
£170·24–£38·63=£131·61. This cost is set against a 
signifi cant diff erence between groups for the primary 
outcome. The net cost per one-point improvement in 
POP-SS was £131·61/1·52, or £86·59. When we consider 
the 95% CI around the diff erence in change in POP-SS 
from baseline (0·46–2·59), the cost per point 
improvement in POP-SS ranges from £51·81 to £286·11. 
When we consider the 95% CI around the net costs 
(£170·24–£126·41 to £170·24+£41·95) the cost per point 
improvement on POP-SS ranges from £28·84 to £139·60.
Discussion
Our fi ndings show a greater reduction in prolapse 
symptoms at 12 months in women who underwent pelvic 
fl oor muscle training than in the control group. This 
diff erence was both statistically signifi cant and of a 
magnitude that would be important to women, because it 
exceeded the minimally important change for the POP-
SS.29 This fi nding was supported by an increase in uptake 
of supplementary treatments (mainly pelvic fl oor muscle 
training) in the control group after 6 months, showing a 
residual need; a reduced prevalence of each individual 
prolapse symptom, and of bladder, bowel, and sexual 
symptoms; and a better quality of life in the intervention 
group after 6 months of muscle training. Furthermore, 
women in the intervention group were more likely to 
report that their prolapse was “better” at both 6 months 
and 12 months. Although more women in the intervention 
group had improvement in prolapse stage, this result did 
not diff er signifi cantly between the groups. Subgroup 
analyses showed that these fi ndings of eff ectiveness held 
irrespective of prolapse stage or type, or the woman’s age 
or attitude towards having surgery. Because of the high 
degree of uptake of some form of pelvic fl oor muscle 
training in the control group before the primary outcome 
assessment at 12 months, and the absence of evidence of 
diff erential use of other non-training interventions, the 
intention-to-treat treatment eff ect estimate could be an 
underestimate of the benefi t associated with pelvic fl oor 
muscle training at 12 months. Therefore, we are confi dent 
that the signifi cant treatment eff ects reported represent 
real eff ects that are of importance to women and 
clinicians. The fi nding that at 12 months, women in the 
control group were as likely to be exercising as were those 
in the intervention group might partly be explained by the 
uptake of physiotherapy in the control group. That almost 
80% of women in the intervention group were still 
exercising at 12 months is encouraging, because long-
term adherence is an important consideration for the 
eff ectiveness of this intervention.
The net cost of the intervention was about £130 per 
woman. The main determinant of the net cost of the 
intervention is its provision. The main area of uncertainty 
is the longer-term eff ect of pelvic fl oor muscle training on 
the need for subsequent treatments such as pessaries, 
6 months 12 months
Intervention (n=225) Control (n=222) p-value Intervention (n=225) Control (n=222) p-value
Interference of prolapse symptoms with:*
Everyday life 1 (0–3), n=188 3 (1–6), n=189 0·001 1 (0–3), n=145 1 (0–4), n=138 0·095
Physical activity 2 (0–5), n=187 3 (0–6), n=189 0·010 1 (0–3), n=128 1 (0–4), n=124 0·251
Social activity 0 (0–3), n=187 1 (0–4), n=189 0·012 0 (0–1), n=128 0 (0–2), n=123 0·173
Personal hygiene 0 (0–2), n=188 1 (0–5), n=189 0·003 0 (0–2), n=128 1 (0–3), n=124 0·079
Interference of prolapse symptoms with sex life
Not at all 75/146 (51%) 53/145 (37%) 0·033† 52/95 (55%) 47/95 (50%) 0·510†
A little 35/146 (24%) 46/145 (32%) .. 25/95 (26%) 29/95 (31%) ..
Somewhat 19/146 (13%) 30/145 (21%) .. 11/95 (12%) 10/95 (10%) ..
A lot 17/146 (12%) 16/145 (11%) .. 7/95 (7%) 9/95 (9%) ..
Bladder symptoms
Urine leakage 103/188 (55%) 129/189 (68%) 0·01 72/132 (54%) 77/128 (60%) 0·430
ICIQ-UI SF score‡ 3 (0–5), n=183 4 (0–7), n=181 <0·0001 3 (0–5), n=126 3 (0–6), n=126 0·118
Bowel symptoms*
Faecal urgency§ 96/188 (51%) 114/189 (60%) 0·041 63/130 (49%) 71/126 (56%) 0·120
Faecal incontinence 42/188 (22%) 47/189 (40%) 0·479 23/130 (18%) 34/127 (27%) 0·072
Data are median (IQR) or n/N (%), unless otherwise indicated. Women were asked to answer questions in relation to the last 4 weeks. ICIQ-UI SF=International Consultation 
on Incontinence Questionnaire Urinary Incontinence Short Form. *Prolapse-related interference scores range from 0 (not at all) to 10 (a great deal). †Mann-Whitney U test 
done on the ordinal response. ‡ICIQ-UI SF score: 0=no incontinence, no interference with everyday life; 21=maximum leakage and interference. §We defi ned faecal urgency as 
sudden, irresistible need to have a bowel movement; faecal incontinence was any involuntary loss of faecal material. 
Table 5: Self-reported eff ect of prolapse symptoms, and prevalence of urinary and bowel symptoms at 6 months and 12 months
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physiotherapy, and surgery; our results are based on the 
trial follow-up period and we cannot exclude the possibility 
that treatments have been delayed rather than avoided. 
Our sensitivity analyses showed plausible ranges around 
our results; however, reasons exist for believing that the 
increased costs are unlikely—namely that expenditure on 
the intervention is a once-only event, as such all costs have 
been incurred and the benefi ts in terms of reduced 
symptoms and treatments avoided are likely to continue 
to accrue over time. In the assumption that women in the 
intervention group gained 10% on their quality of life for a 
year because of the intervention, the cost per quality-
adjusted life-year (QALY) gained is about £16 000. This 
level of cost per QALY is commonly accepted as worthwhile 
by organisations such as the National Institute for Health 
and Clinical Excellence in the UK.
The main strengths of our trial were its size, rigour, and 
pragmatic design, with the intervention being relevant to 
UK NHS practice, and potentially to other similar health 
systems worldwide; furthermore, the outcomes were 
woman-centred. Participants’ compliance with trial 
processes and the intervention were generally high. 
Unlike other trials in this specialty, our main focus was 
the prolapse symptoms that led women to seek treatment, 
and which we used to measure treatment success.
In terms of limitations, we achieved 88% of our target 
sample size of 506, and noted a lower rate of questionnaire 
response than expected at 12 months, despite postal and 
telephone reminders. However, because the SD of the 
POP-SS was smaller than originally assumed, we 
nevertheless had suffi  cient power to identify important 
diff erences. We noted no evidence of diff erential dropout 
because the response rate was similar in both groups, and 
results were also robust to missing data. Not all women 
had a prolapse assessment at 6 months; therefore there 
was also attrition in the POP-Q responses. This attrition 
might have contributed to the non-signifi cant POP-Q 
fi nding. We noted signifi cant crossover of women in the 
control group to the intervention group due to their uptake 
of pelvic fl oor muscle training after 6 months, which 
makes interpretation of the fi ndings more challenging. A 
further limitation is the short follow-up period of 
12 months. Because of natural fl uctuation in prolapse 
symptoms and the eff ect of diff erent treatment modalities, 
clinical and cost diff erences between the groups might be 
expected to change with time. Included women were 
treatment-naive and presented for treatment for the fi rst 
time. However, pelvic fl oor muscle training might also be 
eff ective for enhancement of surgical or pessary treatment, 
or for use after surgical failure, or shortly after childbirth, 
and these situations need further research. In the 
economic analysis we did not estimate QALYs gained 
because fi ndings from our pilot work showed that the SF-
12 was insensitive to meaningful changes in prolapse 
symptoms in this population. Therefore, decision makers 
should interpret the results on the basis of a careful 
reading of the symptoms women suff ered and the extent 
to which these symptoms were relieved. The paucity of 
other economic studies in this specialty makes comparing 
of results diffi  cult; we look forward to future studies that 
provide comparisons for these results.
Six other randomised studies have been published to 
date comparing pelvic fl oor muscle training with a control 
intervention.12,30–34 Three of these trials are pilot trials, 
which makes the drawing of conclusions from their 
fi ndings problematic on the basis of their developmental 
nature and small sample sizes.12,30,31 Three other full-sized 
trials have been published.32–34 The Piya-Anant trial32 had 
methodological limitations and a high risk of bias, and 
cannot reliably contribute to the evidence base. No 
information was provided about the processes of random 
sequence generation or allocation concealment, the 
investigators did not report about attrition and selectively 
reported about only a subgroup of the women randomised, 
and uncertainty existed as to whether the analysis was 
intention to treat. Of the remaining two trials, the 
Brækken single-centre trial33 of pelvic fl oor muscle 
training versus control randomly assigned 109 women 
with stage I–III prolapse, of which a subgroup of only 
69 (63%) women were symptomatic and hence similar to 
our population. The very intensive training regimen 
consisted of weekly appointments for 3 months, followed 
by bi-weekly appointments for 3 months—a treatment 
model that would not be possible to deliver in the UK and 
many other countries because of the restricted availability 
of specialist physiotherapy resource within their health 
services. Kashyap and colleagues34 reported a single-centre 
trial in women with stage I–III prolapse, which compared 
taught pelvic fl oor muscle training plus a self-instruction 
manual (n=70) with the self-instruction manual alone as 
the control intervention (n=70). One person delivered the 
training intervention to all women. The content of the 
manual was not described and therefore what written 
instruction the control group received is unclear. More 
importantly, four women transferred from the control 
group to the training plus manual group; in which group 
these women were analysed is unclear. Until this point is 
clarifi ed, the results have restricted use.
Both Braekken and colleagues33 and Kashyap and 
colleagues34 reported symptom benefi t from pelvic fl oor 
muscle training. Braekken and colleagues analysed the 
subgroup of women with symptoms at baseline and 
reported that women who had received muscle training 
were more likely than women in the control group to 
have reduced frequency of prolapse symptoms (74% vs 
31%) and reduced bother of symptoms (67% vs 42%). 
Kashyap and colleagues reported a signifi cantly greater 
mean reduction in POP-SS score after the intervention 
for the muscle training plus manual group compared 
with the control group (2·99 vs 1·25). Neither trial sought 
evidence about longer term outcomes or the eff ect on the 
uptake of other treatments.
Braekken and colleagues33 also reported that pelvic 
fl oor muscle training improved POP-Q stage: 19% of 
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women in the intervention group had an improved stage 
versus 8% in the control group (11% risk diff erence). Our 
fi nding for POP-Q was non-signifi cant, but of a similar 
size. The most likely reason for the non-signifi cant 
fi nding in our trial is that the study was not powered to 
show a diff erence for this outcome. Data for change in 
the POP-Q or prolapse stage in Kashyap and colleagues’ 
trial were not adequately reported to allow comparison.34
We chose symptom change as our primary outcome 
measure. This endpoint is usually the driver for 
individuals seeking treatment for prolapse and is hence 
the most important outcome for women. That little 
correlation exists between stage of prolapse and the 
prolapse symptoms ascribed to it is increasingly 
recognised.35,36 Therefore, and as we recorded, that an 
improvement in symptoms does not necessarily 
correspond to an improvement in stage is not surprising. 
45% of women in the control group in our study reported 
that their prolapse was better at 12 months. This fi nding 
is partly because about half of these women had received 
further treatment for prolapse by this timepoint. 
Although signifi cantly more women in the intervention 
group than the control group reported that their prolapse 
was better, the remaining participants reported no 
change or worse prolapse. Thus, a substantial group of 
women did not benefi t. One potential reason for this 
fi nding is that a more intensive intervention might be 
needed for some women. Another reason is that some 
types or stages of prolapse do not respond to pelvic fl oor 
muscle training as well as do others, and hence, improved 
selection of women for training might be needed. 
Although our subgroup analyses did not support these 
hypotheses, the analyses were exploratory and 
underpowered to draw fi rm conclusions.
Prolapse can regress with time, which could partly 
explain the improvement we noted. Three studies of the 
epidemiology of prolapse concluded that prolapse can 
both progress and regress.37–39 Handa and colleagues’37 
and Bradley and colleagues’38 studies assessed change in 
severity of prolapse, but in populations older than our 
own. The study by Miedel and colleagues39 is most 
relevant for comparison because it examined both 
symptoms and stage of prolapse over time in women 
with a mean age of 56 years. Their fi ndings show that 
44% of stage I prolapses had regressed to stage 0, 24% of 
stage II showed regression, and 64% (95% CI 56–72) of 
women had a reduction in symptoms by 5 years. 
However, the study population was mainly non-
consulting women identifi ed by a positive questionnaire 
response to “a feeling of a vaginal bulge”, rather than 
women who were actively seeking treatment for prolapse. 
As the investigators mentioned, results cannot be 
automatically generalised to patients who present to 
health-care services. Therefore, we do not know to what 
extent women in our trial naturally improved. However, 
we would expect that any natural regression or 
progression would happen equally in both groups by 
virtue of the group allocation, and hence the noted 
signifi cant diff erences between the groups must be due 
to the intervention.
Our trial is the largest, rigorous, pragmatic multicentre 
trial of pelvic fl oor muscle training for prolapse, with the 
longest follow-up, and as such provides the necessary 
evidence to support changes in clinical practice (panel). 
However the resource implications of implementation of 
these fi ndings should be considered. The physiotherapists 
delivering the trial intervention were specialists in 
women’s health; their numbers are few and their 
workload is large, presently consisting of mainly the 
management of urinary incontinence. With the 
establishment of an evidence-base for pelvic fl oor muscle 
training for the management of prolapse, health-care 
providers will need to invest in extra resources to ensure 
that a similar service can be provided for women with 
prolapse. Additionally, beyond the clinical arena, the role 
of pelvic fl oor muscle exercises for alleviation of prolapse 
symptoms is an important public health message that 
should be shared widely among women of all ages.
We conclude that pelvic fl oor muscle training should 
be recommended for the conservative management of 
prolapse. Eff ectiveness of such training in the long term, 
in women who have had previous prolapse surgery, in 
conjunction with pessary use, and within populations of 
women with diff erent types or combinations of prolapse, 
should be investigated further.
Panel: Research in context
Systematic review
The Cochrane review on the topic of conservative management of prolapse was updated in 
2011 by two of the investigators, before completion of the analysis of the present trial. We 
searched the Cochrane Incontinence Group Specialised Trials Register (May 6, 2010) with 
the search strategy developed for the Cochrane Incontinence Review Group, and CINAHL 
(between Jan 1, 1982, and May 10, 2010), PEDro (January, 2009), the UK National Research 
Register (January 2009), ClinicalTrials.gov (April 2009), Current Controlled Trials register 
(April, 2009), and ZETOC (January, 2009) with the search terms: cystocele, urethrocele, 
rectocele, vault prolapse, uterine prolapse, vaginal prolapse, pelvic organ prolapse, pelvic 
fl oor.  We did not impose any language or other restrictions in any of the searches. Four 
included trials compared pelvic fl oor muscle training with a control intervention,12,30,32,33 but 
two were at signifi cant risk of bias;30, 32 of the remaining two trials, one was the pilot study 
preceding the current trial.12 Prolapse symptoms were measured diff erently in the three 
trials where this was reported;12,30,33 however, all three reported greater improvement in 
symptoms in the training group than the control group. Restricted data from the two trials 
with low risk of bias12,33 suggested that pelvic fl oor muscle training increases the chance of 
an improvement in prolapse stage compared with no training.
Interpretation
Our trial is the largest, rigorous, pragmatic trial of pelvic fl oor muscle training versus 
control for prolapse, and as such provides important robust evidence to inform clinical 
practice. Our fi ndings confi rm those of other smaller or less rigorous studies that such 
training is benefi cial in terms of reducing women’s prolapse symptoms. These fi ndings 
have implications for a range of health-care professionals who care for women with 
prolapse and for women themselves. Long-term benefi ts should be investigated, as should 
the eff ects in specifi c subgroups.
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